DOCM.SW
Hot AirDocMorris AG · Healthcare · Switzerland · $950M cap · $10.3M/day traded
CHF 19.00 +1.4% · close 12 Nov · scored 13 Nov
Hot Air: Strong momentum and nothing else: weak business, rich price.
As of 13 Nov 2026, the MoatMap Score for DocMorris AG (DOCM.SW) is 60/100, ranked against 25,000+ stocks in 38 markets (Quality 39, Value 36, Momentum 82, each scored against its sector).
Does the score work? Each tenth of the ranking, tracked monthly. See the record →
ABOUT DOCMORRIS AG
Read
DocMorris AG operates as an online pharmacy, telemedicine, and healthcare company in Switzerland and internationally.
FINANCIAL SUMMARY (CHF)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 931.0M | 969.5M | 1.0B | 1.1B | 6.5% | 1.2B | 1.3B | 1.4B | 12.3% |
| EPS (CHF) | -3.60 | 3.30 | -1.92 | -3.47 | — | -2.51 | -1.69 | -0.88 | — |
| Shares | 51.0M | 51.0M | 51.0M | 48.1M | -5.6% | 51.0M | — | — | — |
| Debt | 528.6M | 330.8M | 312.2M | 288.6M | -18.3% | 271.0M | — | — | — |
| Equity | 350.8M | 430.5M | 340.1M | 409.1M | 5.3% | — | — | — | — |
| Op CF | -97.3M | -87.4M | -26.6M | -88.6M | — | -55.1M | — | — | — |
| Inv CF | -89.8M | 219.8M | 93.9M | -52.1M | — | — | — | — | — |
| Fin CF | 39.1M | -202.6M | -26.0M | 165.8M | — | — | — | — | — |
Above its 200-day average and 3% below its 52-week high.
Swung more than 74% of stocks we rank over the past year (volatility 60% a year).
How this is worked out
The Price check reads only the chart, the price side of the Momentum score in words; it is not the MoatMap Score.
- Still falling: It set a new 52-week low in the last two weeks, after a deep fall.
- Finding a floor: It fell hard, but has set no new low for more than two weeks.
- Turning up: It has climbed off its low and is back above a rising 50-day average.
- In an uptrend (this stock): It is near its 52-week high and above its 200-day average.
- No clear trend: None of the above: no recent deep fall and no steady climb.
- No read yet: Not enough price history yet: it needs a year of trading.
In past US falls, waiting for Turning up cut the chance of another 20% drop from 42% to 33%. Returns were no better, and 33% of turns failed.
The exact rules
Still falling is a new 52-week low in the last two weeks, at least 25% below the high, with the low set after the high. Finding a floor is the same fall with no new low in the last two weeks. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average, with the 50-day average above the 200-day, and within 15% of the high. No clear trend is everything else. No read yet is under 252 trading days of history, or missing data. A new state shows once it has held for three trading days.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of DOCM.SW are excluded.
| Ticker | Company | Mkt Cap | Score |
|---|---|---|---|
| DOCM.SW | DocMorris AG(you) | $950M | 60 |
| MED.SW | Medartis Holding AG | $1.4B | 55 |
| SKAN.SW | SKAN Group AG | $2.0B | 54 |
| METN.SW | Metall Zug AG | $454M | 46 |
| KURN.SW | Kuros Biosciences AG | $979M | 31 |
| TECN.SW | Tecan Group AG | $3.7B | 66 |
| AEVS.SW | Aevis Victoria SA | $1.5B | 36 |
| CLTN.SW | COLTENE Holding AG | $349M | 75 |
| GALE.SW | Galenica AG | $5.3B | 64 |
| BSLN.SW | Basilea Pharmaceutica AG | $1.0B | 97 |
Peer medians: ROE 10.7% · P/E 37.4x · Gross margin 62.0%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.